SVB Wealth LLC Has $981,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

SVB Wealth LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 40.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,117 shares of the biopharmaceutical company’s stock after acquiring an additional 319 shares during the period. SVB Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $981,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in REGN. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. Sunbelt Securities Inc. acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $25,000. Fortitude Family Office LLC acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $31,000. Bruce G. Allen Investments LLC acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $40,000. Finally, Sutton Wealth Advisors Inc. boosted its position in Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 13 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the topic of a number of research analyst reports. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. Barclays raised their price target on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $976.41.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the sale, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Bonnie L. Bassler sold 827 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at $1,325,338. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,729 shares of company stock valued at $13,124,641. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.3 %

REGN opened at $896.82 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $998.33. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The company has a market cap of $98.43 billion, a P/E ratio of 25.81, a price-to-earnings-growth ratio of 2.58 and a beta of 0.11. The company has a fifty day moving average price of $953.01 and a two-hundred day moving average price of $891.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the previous year, the firm posted $10.96 earnings per share. The business’s revenue was up .6% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.59 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.